Prime Medicine launches with $315 million financing

Cambridge, Massachusetts-based Prime Medicine, a company delivering on the promise of Prime Editing to provide lifelong cures to patients, has announced its launch with $315 million in financing.

The financing comprised a $115 million Series A; based on the rapid progress of the science and the company, Prime Medicine expanded its syndicate support with a $200 million Series B financing around nine months after the company began operations.

Investors in the Series A included ARCH Venture Partners, F-Prime Capital, GV, and Newpath Partners. The Series B included all Series A investors, plus Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board (PSP Investments), Redmile Group, Samsara BioCapital, funds and accounts advised by T Rowe Price Associates, Inc., and a number of additional, unnamed life sciences investment funds.